MCID: INT253
MIFTS: 46

Intestinal Benign Neoplasm

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Intestinal Benign Neoplasm

MalaCards integrated aliases for Intestinal Benign Neoplasm:

Name: Intestinal Benign Neoplasm 12 15
Intestinal Neoplasms 44 70
Neoplasm of Intestinal Tract 12
Intestinal Tumors 12
Intestine Growth 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4610
MeSH 44 D007414
NCIt 50 C3141
SNOMED-CT 67 126769007
UMLS 70 C0021841

Summaries for Intestinal Benign Neoplasm

Disease Ontology : 12 A gastrointestinal system benign neoplasm that is located in the intestine.

MalaCards based summary : Intestinal Benign Neoplasm, also known as intestinal neoplasms, is related to colorectal adenoma and colonic benign neoplasm, and has symptoms including constipation and diarrhea. An important gene associated with Intestinal Benign Neoplasm is APC (APC Regulator Of WNT Signaling Pathway), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Endometrial cancer. The drugs Bisacodyl and Lysine have been mentioned in the context of this disorder. Affiliated tissues include intestine, colon and bone, and related phenotype is neoplasm.

Related Diseases for Intestinal Benign Neoplasm

Diseases related to Intestinal Benign Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 356)
# Related Disease Score Top Affiliating Genes
1 colorectal adenoma 31.9 TP53 PTGS2 MUTYH MIR21 MIR17 MIR15A
2 colonic benign neoplasm 31.8 TP53 PTGS2 MIR20A MIR18A MIR15A MIR143
3 gastric cancer 31.4 TP53 PTGS2 MUTYH MIR21 MIR20A MIR192
4 familial adenomatous polyposis 31.0 TP53 PTGS2 MUTYH KRAS HRAS CTNNB1
5 adenocarcinoma 30.8 TP53 PTGS2 KRAS HRAS CTNNB1 APC
6 adenoma 30.8 TP53 PTGS2 MUTYH KRAS CTNNB1 APC
7 endometriosis 30.4 PTGS2 MIR20A MIR145 MIR143 MIR142
8 desmoid tumor 30.3 PTGS2 MUTYH CTNNB1 APC
9 gastrointestinal stromal tumor 30.3 TP53 PTGS2 KRAS APC
10 peutz-jeghers syndrome 30.2 TP53 CTNNB1 APC
11 colon adenocarcinoma 30.1 TP53 PTGS2 MIR21 KRAS CTNNB1 APC
12 gastric adenocarcinoma 30.1 TP53 PTGS2 KRAS HRAS CTNNB1 APC
13 rasopathy 30.1 TP53 KRAS HRAS CTNNB1
14 lynch syndrome 29.9 TP53 MUTYH MIR532 MIR17 KRAS HRAS
15 gastrointestinal system cancer 29.9 MIR532 MIR21 MIR20A MIR192 MIR18A MIR17
16 rectum cancer 29.8 MUTYH MIR21 MIR20A MIR192 MIR17 MIR145
17 intestinal disease 29.8 TP53 MIR532 MIR21 MIR20A MIR192 MIR18A
18 large intestine adenoma 11.1
19 cecal benign neoplasm 11.1
20 large bowel leiomyoma 11.1
21 large intestine lipoma 11.1
22 hepatic flexure cancer 10.5 KRAS HRAS
23 ampulla of vater benign neoplasm 10.5 KRAS HRAS APC
24 periampullary adenoma 10.5 KRAS HRAS APC
25 trachea carcinoma in situ 10.5 KRAS HRAS
26 signet ring basal cell carcinoma 10.5 KRAS HRAS
27 cobblestone retinal degeneration 10.5 KRAS HRAS
28 serrated polyposis syndrome 10.5 MUTYH KRAS APC
29 immature teratoma of ovary 10.5 KRAS HRAS
30 pancreatic signet ring cell adenocarcinoma 10.5 TP53 KRAS HRAS
31 familial adenomatous polyposis 2 10.5 PTGS2 MUTYH APC
32 feingold syndrome 1 10.5 MIR20A MIR18A MIR17
33 vulvar intraepithelial neoplasia 10.5 TP53 CTNNB1
34 duodenal benign neoplasm 10.5 HRAS APC
35 small intestine adenocarcinoma 10.5 KRAS HRAS CTNNB1
36 bone giant cell sarcoma 10.5 TP53 KRAS HRAS
37 coronavirus infectious disease 10.5 MIR17 H2AC18 CCR6
38 descending colon cancer 10.5 KRAS HRAS
39 biliary tract benign neoplasm 10.5 TP53 KRAS HRAS
40 endometrioid ovary carcinoma 10.5 TP53 KRAS CTNNB1
41 retinal vascular disease 10.5 MIR21 MIR20A MIR17 H2AC18
42 malignant exocrine pancreas neoplasm 10.5 TP53 KRAS HRAS
43 appendix disease 10.5 TP53 KRAS HRAS
44 papillary adenoma 10.5 TP53 KRAS HRAS
45 anogenital venereal wart 10.5 TP53 H2AC18 CCR6
46 appendix cancer 10.5 TP53 KRAS HRAS
47 blood protein disease 10.5 MIR17 H2AC18 CCR6
48 serous cystadenocarcinoma 10.5 TP53 KRAS HRAS
49 aortic disease 10.5 MIR21 MIR17 MIR15A MIR145
50 parasitic helminthiasis infectious disease 10.5 MIR21 H2AC18 CCR6

Graphical network of the top 20 diseases related to Intestinal Benign Neoplasm:



Diseases related to Intestinal Benign Neoplasm

Symptoms & Phenotypes for Intestinal Benign Neoplasm

UMLS symptoms related to Intestinal Benign Neoplasm:


constipation; diarrhea

MGI Mouse Phenotypes related to Intestinal Benign Neoplasm:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.17 APC CTNNB1 HRAS KRAS MUTYH PTGS2

Drugs & Therapeutics for Intestinal Benign Neoplasm

Drugs for Intestinal Benign Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 212)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bisacodyl Approved Phase 4 603-50-9
2
Lysine Approved, Nutraceutical Phase 4 56-87-1 5962
3 Cola Phase 4
4 Gastrointestinal Agents Phase 4
5 Cathartics Phase 4
6 Laxatives Phase 4
7 Pharmaceutical Solutions Phase 4
8
Arginine Investigational, Nutraceutical Phase 4 74-79-3 6322
9
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
10 Orange Approved Phase 3
11
Amoxicillin Approved, Vet_approved Phase 3 26787-78-0 33613
12
Simvastatin Approved Phase 3 79902-63-9 54454
13
Guaifenesin Approved, Investigational, Vet_approved Phase 3 93-14-1 3516
14
Phenylpropanolamine Approved, Vet_approved, Withdrawn Phase 3 14838-15-4 26934
15
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
16
Morphine Approved, Investigational Phase 3 57-27-2 5288826
17
Ondansetron Approved Phase 3 99614-02-5 4595
18
Ofloxacin Approved Phase 3 82419-36-1 4583
19
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
20 Clavulanic Acids Phase 3
21 Amoxicillin-Potassium Clavulanate Combination Phase 3
22 beta-Lactamase Inhibitors Phase 3
23 Anticholesteremic Agents Phase 3
24 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 3
25 Hypolipidemic Agents Phase 3
26 Lipid Regulating Agents Phase 3
27 Calcium, Dietary Phase 3
28 Immunosuppressive Agents Phase 3
29 Anti-Infective Agents Phase 3
30 Anti-Bacterial Agents Phase 3
31 Dermatologic Agents Phase 3
32 Antiemetics Phase 3
33 Neurotransmitter Agents Phase 3
34 Chlorpheniramine, phenylpropanolamine drug combination Phase 3
35 Cytochrome P-450 Enzyme Inhibitors Phase 3
36 Hematinics Phase 3
37 Epoetin alfa Phase 3 113427-24-0
38 Respiratory System Agents Phase 3
39 Narcotics Phase 3
40 Excitatory Amino Acid Antagonists Phase 3
41 Antitussive Agents Phase 3
42 Analgesics, Opioid Phase 3
43 Psychotropic Drugs Phase 3
44 Anti-Anxiety Agents Phase 3
45 Antipsychotic Agents Phase 3
46
Calcium Nutraceutical Phase 3 7440-70-2 271
47
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
48
Carmustine Approved, Investigational Phase 2 154-93-8 2578
49
Cytarabine Approved, Investigational Phase 2 147-94-4 6253
50
Octreotide Approved, Investigational Phase 2 83150-76-9 383414 6400441

Interventional clinical trials:

(show top 50) (show all 153)
# Name Status NCT ID Phase Drugs
1 Phase 4 Study of Comparison of 2-Liter Mixed Preparation With Bisacodyl Plus Polyethylene Glycol and 4-Liter Polyethylene Glycol for Colon Cleansing in Patients With Prior History of Colorectal Resection. A Prospective Randomized Controlled Trial. Completed NCT01887158 Phase 4 Polyethylene glycol;Bisacodyl
2 A Multicenter, Open-label Post Authorization Safety Study to Evaluate the Effect of LysaKare® Infusion on Serum Potassium Levels in GEP-NET Patients Eligible for Lutathera® Treatment Recruiting NCT04524442 Phase 4 arginine/lysine
3 Impact of [68 Ga]-DOTANOC PET-CT on the Management of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): Prospective, Multicentric Study. Unknown status NCT02608203 Phase 2, Phase 3 [68Ga]-DOTANOC PET/CT
4 A Multinational, Randomized, Phase III Study of FOLFIRI With/Without Bevacizumab Versus Irinotecan With/Without Bevacizumab As Second-line Therapy in Patients With Metastatic Colorectal Cancer Unknown status NCT03303495 Phase 3 CPT-11;5-FU Bolus;5-FU Infusion;l-LV (dl-LV)
5 A Prospective Randomised Phase III Trial of Early Hospital Discharge Versus Standard Inpatient Management of Cancer Patients With Low-Risk Febrile Neutropenia Receiving Oral Antibiotics. Oral Antibiotics for Neutropenic Sepsis Giving Early Hospital Discharge [ORANGE] Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
6 Prospective, Double-Blinded, Multi-Centred, Randomised Controlled Trial of Perioperative Simvastatin Use in Elective Colorectal Surgery Completed NCT00994903 Phase 3 Simvastatin;Placebo
7 Combination of Cancer Ablation and Life Information Rehabilitation Therapy for Unresectable Intestinal Cancer Completed NCT03350490 Phase 2, Phase 3 Life information rehabilitation therapy
8 A Multinational, Randomized, Phase III Study of XELIRI With/Without Bevacizumab Versus FOLFIRI With/Without Bevacizumab As Second-line Therapy in Patients With Metastatic Colorectal Cancer Completed NCT01996306 Phase 3 CPT-11 (Irinotecan);5-FU Bolus;5-FU Infusion;l-LV (dl-LV);CPT-11 (Irinotecan);Capecitabine
9 A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy Completed NCT00003600 Phase 3
10 A Phase III Double-Blind Equivalence Study of Two Different Formulations of Slow-Release Morphine Followed by a Randomization Between Dextromethorphan or Placebo Plus Statex SR for Chronic Cancer Pain Relief in Terminally Ill Patients Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
11 Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer Completed NCT00006348 Phase 3 ondansetron
12 A Randomized, Prospective Double-Blind, Placebo-Controlled Trial of Prophylactic Oral Levofloxacin Following Chemotherapy for Lymphoma and Solid Tumors Completed NCT00005590 Phase 3 levofloxacin
13 Randomized, Double-Blinded Phase III Study of Cabozantinib Versus Placebo in Patients With Advanced Neuroendocrine Tumors After Progression on Prior Therapy (CABINET) Recruiting NCT03375320 Phase 3 Cabozantinib S-malate
14 Chemoprevention of Duodenal Polyps in Familial Adenomatous Polyposis Withdrawn NCT00026468 Phase 2, Phase 3 exisulind
15 Is Greater Downstaging and Tumour Regression Observed When Surgery is Delayed to 12 Weeks After Completion of Chemoradiotherapy vs 6 Weeks? Unknown status NCT01037049 Phase 2
16 A Phase II Evaluation of High Dose Chemotherapy and Autologous Stem Cell Transplantation for Intestinal T-cell Lymphomas Unknown status NCT00669812 Phase 2 carmustine;cyclophosphamide;cytarabine;doxorubicin hydrochloride;epirubicin hydrochloride;etoposide;ifosfamide;melphalan;methotrexate;prednisolone;vincristine sulfate
17 A Single Group, Open Label, Multi-center Clinical Trial to Assess the Efficacy and Safety of Anlotinib in Patients With Gastroenteropancreatic Neuroendocrine Tumor G3 Unknown status NCT03457844 Phase 2 Anlotinib
18 Phase 2 Study of Autologous Tumor Lysate-pulsed DC-CIK Cell in Colorectal Cancer After Surgery Unknown status NCT02202928 Phase 2 Chemotherapy
19 Randomized Phase II Study of Brostallicin (PNU-166196A) Versus Doxorubicin as First Line Chemotherapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2 brostallicin;doxorubicin hydrochloride
20 Phase I-II Study of Capecitabine and Oxaliplatin in Combination With Radiotherapy in Patients With Unresectable Gastro-Intestinal Cancer Completed NCT01016639 Phase 1, Phase 2
21 A Phase 2 Trial of Temsirolimus and Bevacizumab in Patients With Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
22 A Phase II Study of Sirolimus, Tacrolimus and Thymoglobulin, as Graft-versus-Host Prophylaxis in Patients Undergoing Unrelated Donor Hematopoietic Cell Transplantation Completed NCT00589563 Phase 2 cyclophosphamide;etoposide;fludarabine phosphate;melphalan;methotrexate;sirolimus;tacrolimus
23 MMT 98 Study For Metastatic Disease Rhabdomyosarcoma And Other Malignant Soft Tissue Sarcoma Of Childhood Completed NCT00025441 Phase 2 carboplatin;cyclophosphamide;doxorubicin hydrochloride;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
24 Phase II Study of Weekly Administered High-Dose Pegylated Interferon Alfa-2B (PEGIntron) in Advanced Stage Low Grade Non-Hodgkin's Lymphoma Completed NCT00006039 Phase 2
25 A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma Completed NCT00433550 Phase 2 capecitabine;irinotecan hydrochloride;oxaliplatin
26 A Pilot Phase I/II Trial of Enteral Wallstents for Duodenal Obstruction in the Setting of Malignancy Completed NCT00004910 Phase 1, Phase 2
27 Pilot Study of Intraperitoneal (IP) Therapy With Cisplatin or Carboplatin and Floxuridine (FUdR) as Consolidation for Ovarian and Gastrointestinal Malignancies Completed NCT00005049 Phase 2 carboplatin;cisplatin;floxuridine
28 Phase II Study on ET-743 in Advanced Soft Tissue Sarcomas of the Adult Completed NCT00003939 Phase 2 trabectedin
29 A Phase 2 Study of GW786034 (Pazopanib) in Advanced Low-Grade or Intermediate-Grade Neuroendocrine Carcinoma Completed NCT00454363 Phase 2 Pazopanib Hydrochloride
30 A Phase I/II Study of Clofarabine in Patients With Relapsed T-Cell and NK-Cell Lymphomas Completed NCT00416351 Phase 1, Phase 2 clofarabine
31 Purine-Analog-Containing Non-Myeloablative Allogeneic Stem Cell Transplantation for Treatment of Hematologic Malignancies and Severe Aplastic Anemia Completed NCT00006379 Phase 2 cyclophosphamide;fludarabine phosphate
32 Dose Finding and Phase II Study of STI 571 in Advanced Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2 imatinib mesylate
33 Phase II Study of RFS 2000 (9-Nitro-Camptothecin, 9-NC) in Patients With Soft-Tissue Sarcomas Completed NCT00005874 Phase 2 rubitecan
34 Treatment of Patients With Hematological Malignancies Using Marrow Transplantation From Unrelated Donors Incompatible for One HLA Locus Antigen Completed NCT00005804 Phase 2 cyclophosphamide
35 Gem-CHOP: A Randomized Phase II Study of Gemcitabine Combined With CHOP in Untreated Aggressive Non-Hodgkin's Lymphoma Completed NCT00079261 Phase 2 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;gemcitabine hydrochloride;prednisone;vincristine sulfate
36 Phase II Trial of 2-Fluorouracil Recombinant Alpha-2a-Interferon and Intravenous Hydroxyurea With Filgrastim in Patients With Refractory GI Malignancies Grant Application Title: Parenteral Hydroxyurea: A Modulator in Pancreatic Cancer Completed NCT00019474 Phase 2 fluorouracil;hydroxyurea
37 A Pilot Phase I/II Trial of Enteral Wallstents for Colonic Obstruction in the Setting of Malignancy Completed NCT00004911 Phase 1, Phase 2
38 Octreotide for Palliation of Inoperable Bowel Obstruction: A Phase II Study Completed NCT00004895 Phase 2 octreotide acetate
39 A Phase II Trial of Gemcitabine and Docetaxel in Patients With Unresectable Leiomyosarcoma Completed NCT00004066 Phase 2 docetaxel;gemcitabine hydrochloride
40 A Multicenter Phase II Study of Continuous Dosing of Sunitinib (Sutent®, SU11248) in Non-GIST Sarcomas Completed NCT00474994 Phase 2 sunitinib malate
41 Evaluation of the Effect of the Ocoxin®-Viusid® Nutritional Supplement on the Quality of Life of Patients With Metastatic Colorectal Adenocarcinoma. Phase II Recruiting NCT03559543 Phase 2
42 A Phase 2 Trial of the CDK4/6 Inhibitor Abemaciclib in Patients With Advanced and Refractory Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEP NETs) Recruiting NCT03891784 Phase 2 Abemaciclib
43 An Open, Single Arm, Multicenter, Exploratory Phase II Clinical Trial of Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type Patients With Metastatic Colorectal Carcinoma as 1st Therapy Recruiting NCT04080843 Phase 2 Anlotinib Hydrochloride;Capecitabine;Oxaliplatin
44 Stereotactic Body Radiation Therapy for the Treatment of Unresectable Liver Metastases in Patients With Colorectal Adenocarcinoma, Carcinoma of the Anal Canal and Gastrointestinal Neuroendocrine Tumors Recruiting NCT02185443 Phase 2
45 NEOadjuvant Chemotherapy Only Compared With Standard Treatment for Locally Advanced Rectal Cancer: a Randomized Phase II Trial Recruiting NCT03280407 Phase 2 Capecitabine;FOLFOX regimen (oxaliplatin/leucovorin/5FU);CAPOX (oxaliplatin/capecitabine)
46 Apatinib Versus Bevacizumab in Combination With Second-line FOLFIRI in Patients With Metastatic Colorectal Cancer That Progressed During or After First-line Bevacizumab Plus an Oxaliplatin-based Regimen: A Randomised Phase 2 Trial Recruiting NCT03271255 Phase 2 Apatinib Mesylate Tablets;Bevacizumab Injection
47 A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors Recruiting NCT03037385 Phase 1, Phase 2 pralsetinib (BLU-667)
48 Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors Active, not recruiting NCT01841736 Phase 2 Pazopanib Hydrochloride
49 Phase II Study of Intrathecal I-3F8 in Patients With GD2-Expressing Central Nervous System and Leptomeningeal Neoplasms Active, not recruiting NCT00445965 Phase 2
50 Phase Ib/II Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors Active, not recruiting NCT03043664 Phase 1, Phase 2 Somatuline Depot;Keytruda

Search NIH Clinical Center for Intestinal Benign Neoplasm

Cochrane evidence based reviews: intestinal neoplasms

Genetic Tests for Intestinal Benign Neoplasm

Anatomical Context for Intestinal Benign Neoplasm

The Foundational Model of Anatomy Ontology organs/tissues related to Intestinal Benign Neoplasm:

19
Intestine

MalaCards organs/tissues related to Intestinal Benign Neoplasm:

40
Colon, Bone, Small Intestine, Lung, Liver, Thyroid, Ovary

Publications for Intestinal Benign Neoplasm

Articles related to Intestinal Benign Neoplasm:

(show top 50) (show all 152)
# Title Authors PMID Year
1
Transforming growth factor beta receptor type II inactivation induces the malignant transformation of intestinal neoplasms initiated by Apc mutation. 54 61
17047044 2006
2
Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity. 61 54
12460911 2002
3
MicroRNAs as Predictive Biomarkers of Resistance to Targeted Therapies in Gastrointestinal Tumors. 61
33801049 2021
4
Ovarian mucinous neoplasms, intestinal type, in premenopausal patients, develop in abnormal ovaries. 61
33227313 2021
5
Diagnostic accuracy of positive oral contrast in abdominal computed tomography for non-traumatic pathologies: a systematic review protocol. 61
33577231 2021
6
Decorin deficiency promotes epithelial-mesenchymal transition and colon cancer metastasis. 61
33065248 2021
7
Retrospective analysis of the Zebrafish International Resource Center diagnostic data links Pseudocapillaria tomentosa to intestinal neoplasms in zebrafish Danio rerio (Hamilton 1822). 61
32892418 2020
8
De Novo Development of Distal Jejunal and Duodenal Adenomas After 41 Months of Teduglutide Treatment in a Patient With Short-Bowel Syndrome: A Case Report. 61
32740933 2020
9
Kaposiform hemangioma of jejunum in a newborn: A case report and review of literature. 61
33074134 2020
10
Large esophageal schwannoma: En-bloc resection with primary closure by esophagoplasty. 61
31351369 2019
11
Heterozygosity of Chaperone Grp78 Reduces Intestinal Stem Cell Regeneration Potential and Protects against Adenoma Formation. 61
30232220 2018
12
Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of gastrointestinal stromal tumors of dogs. 61
30307656 2018
13
The Intestinotrophic Effects of Glucagon-Like Peptide-2 in Relation to Intestinal Neoplasia. 61
29741675 2018
14
Transmission of a common intestinal neoplasm in zebrafish by cohabitation. 61
29023774 2018
15
Primary neoplasms of the small bowel at CT: a pictorial essay for the clinician. 61
29461587 2018
16
Hypothesis: Induction of biomarkers for detection of colonic neoplasms. 61
29290782 2018
17
A Peutz-Jeghers syndrome family associated with sinonasal adenocarcinoma: 28 years follow up report. 61
28391433 2017
18
Burkitt lymphoma as a lead point for jejunojejunal intussusception in a human immunodeficiency virus patient. 61
28523628 2017
19
Transposon mutagenesis identifies candidate genes that cooperate with loss of transforming growth factor-beta signaling in mouse intestinal neoplasms. 61
27790711 2017
20
Intestinal cancer stem cells marked by Bmi1 or Lgr5 expression contribute to tumor propagation via clonal expansion. 61
28176811 2017
21
Altered T-Cell Balance in Lymphoid Organs of a Mouse Model of Colorectal Cancer. 61
27798287 2016
22
[Application of magnetic resonance enterography for diagnosis of small intestinal diseases in children]. 61
26791925 2016
23
Immunohistochemical characterization of intestinal neoplasia in zebrafish Danio rerio indicates epithelial origin. 61
26503773 2015
24
One stage curative resection of double intestinal neuroendocrine tumors with thirty-two bilobar liver metastases. A case report. 61
26344670 2015
25
NON-CELIAC SPRUE: A CASE OF OLMESARTAN-INDUCED ENTEROPATHY. 61
27159470 2015
26
Foot infection by Clostridium sordellii: case report and review of 15 cases in France. 61
25609723 2015
27
Recent advances in intestinal lymphomas. 61
25639480 2015
28
The hierarchical model of stem cell genesis explains the man mouse paradox, Peto's paradox, the red cell paradox and Wright's enigma. 61
25459141 2014
29
Polypoid arteriovenous malformation presenting with jejunojejunal intussusceptions in an adult. 61
25505727 2014
30
A chronic oral reference dose for hexavalent chromium-induced intestinal cancer. 61
23943231 2014
31
Interplay of host microbiota, genetic perturbations, and inflammation promotes local development of intestinal neoplasms in mice. 61
24590763 2014
32
Pediatric ileoileal intussusception with a lipoma lead point: a case report. 61
24760240 2014
33
Pediatric and adult celiac disease: similarities and differences. 61
23715643 2013
34
Candidate serum biomarkers for early intestinal cancer using 15N metabolic labeling and quantitative proteomics in the ApcMin/+ mouse. 61
23924158 2013
35
Genetic control of intestinal stem cell specification and development: a comparative view. 61
22529012 2012
36
Monoallelic silencing and haploinsufficiency in early murine intestinal neoplasms. 61
22308460 2012
37
Intestinal cancer in inflammatory bowel disease: natural history and surveillance guidelines. 61
24714149 2012
38
Alginate-folic acid-modified chitosan nanoparticles for photodynamic detection of intestinal neoplasms. 61
21163518 2011
39
C57BL/KsJ-db/db-Apc mice exhibit an increased incidence of intestinal neoplasms. 61
22174655 2011
40
Diffuse infantile hemangiomatosis of the ileum presenting with multiple perforations: a case report and review of the literature. 61
20850639 2010
41
[Clinicopathological features of small intestinal tumors]. 61
20716865 2010
42
Surgical treatment of small bowel neoplasms. 61
20496543 2010
43
Chemoprevention of colorectal cancer by targeting APC-deficient cells for apoptosis. 61
20348907 2010
44
Aberrant DNA methylation occurs in colon neoplasms arising in the azoxymethane colon cancer model. 61
19777566 2010
45
PKCalpha tumor suppression in the intestine is associated with transcriptional and translational inhibition of cyclin D1. 61
19232344 2009
46
TGF-beta receptor inactivation and mutant Kras induce intestinal neoplasms in mice via a beta-catenin-independent pathway. 61
19208363 2009
47
The epidemiology and pathogenesis of neoplasia in the small intestine. 61
19064190 2009
48
N-Methyl-N-Nitrosourea (MNU): A positive control chemical for p53+/- mouse carcinogenicity studies. 61
18827072 2008
49
Primary melanoma of small intestine masquerading as gastrointestinal stromal tumor: a case report and literature review. 61
18453296 2008
50
Colorectal cancer risk in Crohn's disease. 61
18350616 2008

Variations for Intestinal Benign Neoplasm

Expression for Intestinal Benign Neoplasm

Search GEO for disease gene expression data for Intestinal Benign Neoplasm.

Pathways for Intestinal Benign Neoplasm

Pathways related to Intestinal Benign Neoplasm according to GeneCards Suite gene sharing:

(show all 25)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.84 TP53 PTGS2 KRAS HRAS CTNNB1 APC
2
Show member pathways
12.69 TP53 KRAS HRAS CTNNB1 APC
3 12.64 TP53 PTGS2 KRAS HRAS CTNNB1 APC
4
Show member pathways
12.63 TP53 KRAS HRAS CTNNB1 APC
5
Show member pathways
12.51 TP53 PTGS2 KRAS HRAS CTNNB1 APC
6
Show member pathways
12.34 TP53 KRAS HRAS CTNNB1
7
Show member pathways
12.29 PTGS2 KRAS HRAS CTNNB1
8
Show member pathways
12.26 TP53 MIR20A MIR18A MIR17
9
Show member pathways
12.22 TP53 KRAS HRAS CTNNB1
10
Show member pathways
12.16 TP53 HRAS CTNNB1 APC
11 12.08 TP53 MIR21 KRAS HRAS CTNNB1
12 11.95 KRAS HRAS CTNNB1 APC
13 11.94 TP53 PTGS2 KRAS CTNNB1 APC
14 11.93 TP53 PTGS2 MIR21 MIR20A MIR192 MIR18A
15 11.87 KRAS HRAS CTNNB1 APC
16 11.84 TP53 KRAS HRAS CTNNB1
17 11.72 TP53 KRAS HRAS CTNNB1 APC
18 11.71 MIR20A MIR18A MIR17
19 11.62 TP53 KRAS HRAS
20 11.6 TP53 KRAS HRAS CTNNB1 APC
21 11.58 TP53 KRAS HRAS
22 11.56 TP53 KRAS HRAS
23 11.37 PTGS2 KRAS HRAS
24 10.74 KRAS HRAS
25 10.73 KRAS HRAS CTNNB1 APC

GO Terms for Intestinal Benign Neoplasm

Cellular components related to Intestinal Benign Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.65 MIR532 MIR21 MIR20A MIR192 MIR18A MIR17
2 beta-catenin destruction complex GO:0030877 9.26 CTNNB1 APC
3 Wnt signalosome GO:1990909 9.16 CTNNB1 APC
4 extracellular vesicle GO:1903561 9.02 MIR21 MIR20A MIR192 MIR17 MIR15A

Biological processes related to Intestinal Benign Neoplasm according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.03 TP53 MIR21 KRAS HRAS CTNNB1
2 positive regulation of apoptotic process GO:0043065 9.88 TP53 PTGS2 MIR21 MIR15A CTNNB1 APC
3 negative regulation of gene expression GO:0010629 9.85 TP53 MIR21 MIR20A MIR17 HRAS CTNNB1
4 negative regulation of inflammatory response GO:0050728 9.81 MIR20A MIR15A MIR145 MIR142
5 Ras protein signal transduction GO:0007265 9.8 TP53 KRAS HRAS
6 negative regulation of cell proliferation GO:0008285 9.8 TP53 PTGS2 MIR21 MIR15A HRAS CTNNB1
7 positive regulation of osteoblast differentiation GO:0045669 9.77 MIR21 MIR20A CTNNB1
8 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.76 MIR21 MIR15A APC
9 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.74 MIR21 MIR20A MIR17
10 negative regulation of angiogenesis GO:0016525 9.72 MIR21 MIR15A MIR145 MIR143 CTNNB1
11 negative regulation of cardiac muscle cell apoptotic process GO:0010667 9.7 MIR21 MIR20A MIR145
12 negative regulation of sprouting angiogenesis GO:1903671 9.67 MIR20A MIR18A MIR17
13 negative regulation of vascular endothelial growth factor production GO:1904046 9.65 MIR20A MIR17 MIR15A
14 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.63 MIR20A MIR17
15 positive regulation of vascular associated smooth muscle cell migration GO:1904754 9.63 MIR21 MIR20A MIR143
16 positive regulation of metalloendopeptidase activity GO:1904685 9.62 MIR21 MIR17
17 endothelial tube morphogenesis GO:0061154 9.61 MIR21 CTNNB1
18 angiotensin-activated signaling pathway GO:0038166 9.61 MIR145 MIR143
19 response to isolation stress GO:0035900 9.59 KRAS HRAS
20 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.58 MIR21 MIR17
21 aorta smooth muscle tissue morphogenesis GO:0060414 9.56 MIR145 MIR143
22 negative regulation of interleukin-21 production GO:0032705 9.55 MIR21 MIR192
23 miRNA mediated inhibition of translation GO:0035278 9.55 MIR21 MIR20A MIR17 MIR15A MIR145
24 regulation of phenotypic switching GO:1900239 9.54 MIR145 MIR143
25 establishment or maintenance of cell type involved in phenotypic switching GO:0044663 9.43 MIR145 MIR143
26 gene silencing by miRNA GO:0035195 9.36 MIR532 MIR21 MIR20A MIR192 MIR18A MIR17
27 positive regulation of pulmonary blood vessel remodeling GO:1905111 9.13 MIR20A MIR17 MIR143

Molecular functions related to Intestinal Benign Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.65 MIR21 MIR20A MIR192 MIR18A MIR17 MIR15A
2 RNA polymerase II complex binding GO:0000993 9.33 MIR20A MIR145 MIR139
3 mRNA 3'-UTR binding GO:0003730 9.28 TP53 MIR21 MIR20A MIR17 MIR15A MIR145

Sources for Intestinal Benign Neoplasm

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....